Skip to main content
. 2020 Jul 12;79(10):1310–1319. doi: 10.1136/annrheumdis-2020-217372

Figure 3.

Figure 3

Additional efficacy outcomes—American College of Rheumatology (ACR) and Psoriasis Area and Severity Index (PASI). Percentage of patients achieving (A) ACR20, (B) ACR70, (C) PASI75 and (D) PASI90, through 52 weeks. Ixekizumab (IXE) vs adalimumab (ADA): †p<0.01, ‡p<0.001.